Norifumi Kawada Selected Research

Antiviral Agents (Antivirals)

12/2023	Posttreatment liver function, but not baseline liver function stratifies patient survival after direct-acting antiviral treatment in decompensated cirrhosis with hepatitis C virus.
10/2023	Recent Advances in the Pathogenesis and Clinical Evaluation of Portal Hypertension in Chronic Liver Disease.
10/2023	Real-world treatment outcome with protease inhibitor direct-acting antiviral in advanced hepatitis C cirrhosis: a REAL-C study.
1/2023	Risk factors for liver-related and non-liver-related mortality following a sustained virological response after direct-acting antiviral treatment for hepatitis C virus infection in a real-world cohort.
1/2023	Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis.
1/2022	Direct-acting antivirals reduce the risk of tumour progression of hepatocellular carcinoma after curative treatment.
1/2022	Liver-related events after direct-acting antiviral therapy in patients with hepatitis C virus-associated cirrhosis.
11/2021	Postoperative direct-acting antiviral treatment after liver resection in patients with hepatitis C virus-related hepatocellular carcinoma.
2/2021	Combination of Entecavir or Tenofovir with Pegylated Interferon-α for Long-Term Reduction in Hepatitis B Surface Antigen Levels: Simultaneous, Sequential, or Add-on Combination Therapy.
1/2021	Association of serum autotaxin levels with liver fibrosis in patients pretreatment and posttreatment with chronic hepatitis C.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Norifumi Kawada Research Topics

Disease

58	Fibrosis (Cirrhosis) 12/2023 - 05/2003
46	Hepatocellular Carcinoma (Hepatoma) 02/2024 - 03/2002
40	Liver Cirrhosis (Hepatic Cirrhosis) 05/2022 - 11/2002
35	Infections 01/2023 - 04/2006
30	Chronic Hepatitis C 01/2021 - 10/2003
29	Neoplasms (Cancer) 08/2023 - 02/2007
20	Chronic Hepatitis B 10/2023 - 02/2005
19	Liver Diseases (Liver Disease) 01/2023 - 03/2006
17	Non-alcoholic Fatty Liver Disease 11/2023 - 03/2006
16	Hepatitis 10/2023 - 05/2003
9	Fatty Liver 01/2021 - 03/2007
8	Inflammation (Inflammations) 01/2024 - 01/2009
7	Necrosis 01/2021 - 02/2003
7	Carcinogenesis 01/2017 - 08/2011
6	Chronic Hepatitis (Chronic Active Hepatitis) 03/2016 - 04/2007
5	Hepatitis B 01/2019 - 12/2008
4	Hepatitis C 10/2023 - 01/2009
4	Neoplasm Metastasis (Metastasis) 01/2022 - 06/2012
4	Cholestasis 02/2021 - 01/2017
4	Alcoholic Fatty Liver 10/2020 - 03/2011
4	Virus Diseases (Viral Diseases) 07/2020 - 01/2013
4	Disease Progression 06/2014 - 03/2006
4	Insulin Resistance 03/2012 - 03/2007
3	Liver Neoplasms (Liver Cancer) 10/2023 - 11/2012
3	Hypertension (High Blood Pressure) 10/2023 - 10/2017
3	Cholangiocarcinoma 08/2023 - 07/2014
3	Hypoxia (Hypoxemia) 08/2019 - 05/2013
2	Obesity 11/2023 - 01/2022
2	Chronic Renal Insufficiency 10/2023 - 01/2020
2	Portal Hypertension 01/2023 - 02/2021
2	Pancreatic Neoplasms (Pancreatic Cancer) 05/2022 - 01/2018
2	Hepatic Encephalopathy 01/2022 - 05/2018
2	Hemorrhage 01/2021 - 01/2021

Drug/Important Bio-Agent (IBA)

29	Antiviral Agents (Antivirals)IBA 12/2023 - 01/2009
27	InterferonsIBA 12/2019 - 03/2007
17	CytoglobinIBA 05/2022 - 02/2007
15	Biomarkers (Surrogate Marker)IBA 10/2023 - 02/2011
13	Ribavirin (Virazole)FDA LinkGeneric 10/2023 - 01/2008
11	Proteins (Proteins, Gene)FDA Link 12/2022 - 03/2002
11	CollagenIBA 07/2021 - 10/2003
11	Thioacetamide (Thioacetamid)IBA 01/2021 - 05/2003
10	entecavir FDA Link 10/2023 - 12/2008
9	MicroRNAs (MicroRNA)IBA 12/2022 - 11/2012
9	lenvatinibIBA 12/2022 - 08/2019
8	GlobinsIBA 01/2022 - 08/2011
8	Amino Acids FDA Link 01/2021 - 06/2004
7	Hepatitis B Surface Antigens (HBsAg)FDA Link 02/2024 - 02/2005
7	Messenger RNA (mRNA)IBA 12/2022 - 03/2007
7	Choline (Choline Chloride)IBA 01/2021 - 02/2010
6	Transforming Growth Factors (Transforming Growth Factor)IBA 11/2020 - 06/2012
6	DNA (Deoxyribonucleic Acid)IBA 01/2018 - 11/2007
6	Lamivudine (Epivir)FDA Link 08/2015 - 02/2005
5	NucleosidesIBA 02/2024 - 09/2008
5	Indicators and Reagents (Reagents)IBA 12/2022 - 11/2011
5	Carbon Tetrachloride (Tetrachloromethane)IBA 01/2022 - 10/2003
5	Alanine Transaminase (SGPT)IBA 01/2021 - 01/2009
5	AntigensIBA 01/2019 - 03/2007
4	Hemoglobins (Hemoglobin)IBA 10/2023 - 03/2007
4	AlbuminsIBA 10/2023 - 02/2003
4	Immune Checkpoint ProteinsIBA 10/2022 - 01/2020
4	Reactive Oxygen Species (Oxygen Radicals)IBA 05/2022 - 01/2020
4	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2008
4	Methionine (L-Methionine)FDA Link 01/2021 - 11/2007
4	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2021 - 01/2009
4	Tenofovir (Viread)FDA Link 01/2020 - 04/2013
4	CytokinesIBA 12/2018 - 03/2007
4	Hepatitis B e AntigensIBA 05/2018 - 09/2008
4	CholesterolIBA 06/2012 - 03/2007
3	Triglycerides (Triacylglycerol)IBA 11/2023 - 01/2012
3	Fetal Proteins (Fetoprotein)IBA 01/2023 - 01/2017
3	SofosbuvirIBA 01/2023 - 01/2018
3	Cysteine (L-Cysteine)FDA Link 05/2022 - 11/2002
3	nasIBA 02/2021 - 01/2009
3	LipidsIBA 01/2021 - 03/2012
3	Collagen Type IV (Type IV Collagen)IBA 01/2021 - 02/2011
3	Carrier Proteins (Binding Protein)IBA 06/2020 - 10/2013
3	Sorafenib (BAY 43-9006)FDA Link 01/2020 - 01/2013
3	Insulin (Novolin)FDA Link 08/2019 - 02/2011
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 11/2018 - 04/2006
3	Branched-Chain Amino AcidsIBA 05/2018 - 07/2009
3	Monoclonal AntibodiesIBA 01/2013 - 03/2002
3	halofuginoneIBA 10/2010 - 02/2007
3	Transforming Growth Factor beta (TGF-beta)IBA 05/2009 - 07/2005
3	AntibodiesIBA 01/2009 - 03/2002
3	ThioredoxinsIBA 01/2005 - 05/2003
2	NucleotidesIBA 02/2024 - 01/2018
2	Cytidine Triphosphate (CTP)IBA 10/2023 - 07/2009
2	velpatasvirIBA 01/2023 - 01/2021
2	Tyrosine Kinase InhibitorsIBA 12/2022 - 08/2019
2	AntioxidantsIBA 05/2022 - 01/2021
2	3-nitrotyrosineIBA 11/2020 - 08/2011
2	sofosbuvir drug combination ledipasvirIBA 10/2020 - 01/2018
2	wisteria lectinIBA 06/2020 - 10/2017
2	Ursodeoxycholic Acid (Urso)FDA LinkGeneric 01/2020 - 12/2019

Therapy/Procedure

67	Therapeutics 02/2024 - 10/2003
5	Aftercare (After-Treatment) 01/2021 - 01/2013
4	Ligation 01/2021 - 02/2008
3	Drug Therapy (Chemotherapy) 06/2023 - 02/2007
2	Immunotherapy 06/2023 - 01/2023
2	Liver Transplantation 07/2021 - 07/2009